Pyrazolopyrimidines as cyclin dependent kinase inhibitors

Organic compounds -- part of the class 532-570 series – Organic compounds – Nitrogen attached directly or indirectly to the purine ring...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

Reexamination Certificate

active

07067661

ABSTRACT:
In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

REFERENCES:
patent: 5571813 (1996-11-01), Rühter et al.
patent: 5602136 (1997-02-01), Rühter et al.
patent: 5602137 (1997-02-01), Rühter et al.
patent: 5688949 (1997-11-01), Inoue et al.
patent: 5707997 (1998-01-01), Shoji et al.
patent: 5919815 (1999-07-01), Bradley et al.
patent: 6040321 (2000-03-01), Kim et al.
patent: 6191131 (2001-02-01), He et al.
patent: 6262096 (2001-07-01), Kim et al.
patent: 6413974 (2002-07-01), Dumont et al.
patent: 102 23 917 (2003-12-01), None
patent: 0 591 528 (1994-04-01), None
patent: 0 628 559 (2002-04-01), None
patent: 1 334 973 (2003-08-01), None
patent: 03 204 877 (1991-09-01), None
patent: 03204877 (1991-09-01), None
patent: WO 95/35298 (1995-12-01), None
patent: WO 02/40485 (2002-05-01), None
patent: WO 02/50079 (2002-06-01), None
patent: WO 02/060492 (2002-08-01), None
patent: WO 03/091256 (2003-11-01), None
patent: WO 2004/022559 (2004-03-01), None
Senderowicz et al., “Preclinical and Clinical Development of Cyclin-Dependent Kinase Modulators”,National Cancer Institute, 92(5): 376-387, Mar. 1, 2000.
Translation of WO 03/91256, (62 pages).
Vesely et al., “Inhibition of Cyclin-Dependent Kinases by Purine Analogues”,Eur. J. Biochem(1994), 224: 771-786.
Kim et al., “Discovery of Aminothiazole Inhibitors of Cyclin-Dependent Kinase 2: Synthesis, X-ray Crystallographic Analysis, and Biological Activities”,Journal of Medical Chemistry, Page EST:22.3, A-W.
Melley et al., “Aloisines, a New Family of CDK/GSK-3 Inhibitors. SAR Study, Crystal Structure in Complex with CDK2, Enzyme Selectivity, and Cellular Effects”,J. Med. Chem.(2003), 46(2):222-236.
Navinson et al., “Synthesis and Antifungal Properties of Certain 7-Aklylaminopyrazolo[1,5-α]pyrimidines”,J. Med. Chem.(1977), 20(2):296-299.
Senderowicz et al., “Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Patients with Refractory Neoplasms”,Journal of Clinical Oncology(Sep. 1998), 16(9): 2986-2999.
Meijer et al., “Biochemical and Cellular Effects of Roscavitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases CDC2, CDK2 and CDK5”,Eur. J. Biochem.(1997), 243:527-536.
Bible et al., “Cytotoxic Synergy Between Flavopiridol (NSC 649890, L86-8275) and Various Antineoplastic Agents: The Importance of Sequence of Administration”,Cancer Research(Aug. 15, 1997), 57: 3375-3380.
Shiota et al., “Synthesis and Structure-Activity Relationship of a New Series of Potent Angiotensin II Receptor Antagonists: Pyrazolo[1,5-α]pyrimidine Derivatives”,Chem. Pharm. Bull.(1999), 47(7):928-938.
Yasuo Makizumi, “Studies on the Azaindolizine Compounds. XI. Synthesis of 6,7-Disubstituted Pyrazolo[1,5-α]pyrimidines.”,Chem. Pharm. Bull(1962), 10:620-626.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Pyrazolopyrimidines as cyclin dependent kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyrazolopyrimidines as cyclin dependent kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazolopyrimidines as cyclin dependent kinase inhibitors will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3669234

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.